Kyongbo Pharmaceutical

At a glance

Kyongbo Pharmaceutical filed 33 disclosures in the last 12 months, including 5 insider, 3 earnings, 2 5% holder and 1 contract. The most recent key filing was on Oct 30: Operating profit ₩100M, down 78.9% YoY. Revenue ₩66.2B, down 1.2% YoY.

Revenue for 2025 was ₩264B, up 10.7% on 2024. Operating margin was 1.3% against 4.4% a year earlier. Debt was 119% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩141B and operating profit of ₩1.6B.

The 2025 annual report lists 571 employees with an average tenure of 8 years and average pay of ₩75M, #482 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩219M each on average. It paid ₩50 per common share in cash dividends, against ₩50 a year earlier (+0%). (주)종근당홀딩스 and related parties held 60.56% at year end.

From the 2025 annual report

Staff: 571 (438 men, 133 women), of whom 13 on fixed-term contracts. Total pay for the year: ₩42.6B. Directors and auditors: 5, paid ₩1.1B in total.

Dividends (common shares)

Largest shareholder

(주)종근당홀딩스 holds 43.41%; with 7 related parties the group holds 60.56% of common shares at year end (from 60.50% at the start of the year).

Auditor: 이촌회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary